Seminar - How big are the mortality reductions produced by cancer screening?
23 February 2012
Full title: How big are the mortality reductions produced by cancer screening? Why do so many trials report only 20%?
Speaker:Professor James Hanley, McGill University
Abstract
Influential reports on the reductions produced by screening for cancers of the prostate, colon and lung have appeared recently. The reported reductions in these randomized trials have been modest, and smaller than expected. But even more surprisingly, all three figures are very similar. I explain why these figures are underestimates and why the seemingly-universal 20% reduction is an artifact of the prevailing data-analysis methods and stopping rules. A different approach to the analysis of data from cancer screening trials is called for.
For more details, see the Reprints/talks tab in the presenter's homepage
http://www.medicine.mcgill.ca/epidemiology/hanley/
Hosted by Screening & Test Evaluation Program (STEP), School of Public Health
Time: 1 - 2pm
Location: Chemistry Lecture Theatre 4, University of Sydney
Contact: Jessica Frazer
Phone: 02 9351 5994
Email: 590823262e2457692a2b251135230429230a5e082177570200612c27